TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion

Summary

This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with hepatocellular carcinoma (HCC) invading the portal vein. The study aims to evaluate the effects on tumor load, angiogenesis, and survival outcomes.

Timeline

Start

2021-06-01

Primary completion

2024-03-31

Completion

2025-05-30

Drugs

Indications